Screener
Bausch + Lomb BLCO Pharmaceuticals — Goodwill, Foreign Currency Translation, Gain (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001860742-26-000088
| (in millions) | Vision Care | Pharmaceuticals | Surgical | Total |
|---|---|---|---|---|
| Balance, January 1, 2025 | $3,529 | $644 | $350 | $4,523 |
| Acquisitions (Note 5) | — | — | 97 | 97 |
| Foreign exchange and other | 26 | 100 | 12 | 138 |
| Balance, December 31, 2025 | 3,555 | 744 | 459 | 4,758 |
| Acquisitions | 4 | — | — | 4 |
| Foreign exchange and other | (11) | (24) | (4) | (39) |
| Balance, June 30, 2026 | $3,548 | $720 | $455 | $4,723 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss)?
- Bausch + Lomb (BLCO) reported pharmaceuticals — goodwill, foreign currency translation, gain (loss) of $11M in Q2 2026.
- How has Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss) changed year-over-year?
- Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss) increased by 115.5% year-over-year, from -$71M to $11M.
- What is the long-term trend for Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss)?
- Over 3 years (2021 to 2025), Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss) has grown at a 95.7% compound annual growth rate (CAGR), from $14M to -$105M.
- What does pharmaceuticals — goodwill, foreign currency translation, gain (loss) mean?
- Captures the impact of exchange rate fluctuations on the carrying value of goodwill denominated in foreign currencies within the pharmaceutical segment. It reflects non-operating volatility that arises when reporting international pharmaceutical assets in the company's functional reporting currency.
Ask your AI about Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude